Featured Research

from universities, journals, and other organizations

Educational toolkit did not improve quality of care or outcomes for patients with diabetes

Date:
February 4, 2014
Source:
PLOS
Summary:
An educational toolkit designed to improve care of patients with diabetes was not effective, researchers found in a cluster randomized trial conducted in 2009-2011. During 10 months of follow-up, patients of Canadian family physicians who had been cluster-randomized to receive the toolkit did not receive improved care and their outcomes did not differ compared with patients of physicians who did not receive the toolkit.

An educational toolkit designed to improve care of patients with diabetes was not effective, Baiju R Shah and colleagues (University of Toronto) found in a cluster randomized trial conducted in 2009-2011. During 10 months of follow-up, patients of Canadian family physicians who had been cluster-randomized to receive the toolkit did not receive improved care and their outcomes did not differ compared with patients of physicians who did not receive the toolkit.

All 933,789 people aged ≥40 years with diagnosed diabetes in Ontario, Canada, were studied using population-level administrative databases and evaluated for the primary outcome in the administrative data study, death or non-fatal myocardial infarction. This composite outcome occurred in 11,736 (2.5%) patients in the intervention group and 11,536 (2.5%) in the control group (p = 0.77). Additional clinical outcome data was collected from a random sample of 1,592 high risk patients.

The primary outcome in this clinical data study was use of a statin; this occurred in 700 (88.1%) patients in the intervention group and 725 (90.1%) in the control group (p = 0.26). Other secondary outcomes, including other clinical events, were also not improved by the intervention.

In a few cases the educational toolkit was actually associated with slightly worse process-of-care outcomes. A limitation was that a very high proportion of the high risk patients in the clinical study group were already prescribed statins. The authors conclude, "The results of this study highlight the need for a rigorous and scientifically based approach to the development, dissemination, and evaluation of quality improvement interventions."


Story Source:

The above story is based on materials provided by PLOS. Note: Materials may be edited for content and length.


Journal Reference:

  1. Baiju R. Shah, Onil Bhattacharyya, Catherine H. Y. Yu, Muhammad M. Mamdani, Janet A. Parsons, Sharon E. Straus, Merrick Zwarenstein. Effect of an Educational Toolkit on Quality of Care: A Pragmatic Cluster Randomized Trial. PLoS Medicine, 2014; 11 (2): e1001588 DOI: 10.1371/journal.pmed.1001588

Cite This Page:

PLOS. "Educational toolkit did not improve quality of care or outcomes for patients with diabetes." ScienceDaily. ScienceDaily, 4 February 2014. <www.sciencedaily.com/releases/2014/02/140204185649.htm>.
PLOS. (2014, February 4). Educational toolkit did not improve quality of care or outcomes for patients with diabetes. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/02/140204185649.htm
PLOS. "Educational toolkit did not improve quality of care or outcomes for patients with diabetes." ScienceDaily. www.sciencedaily.com/releases/2014/02/140204185649.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins